3 recruiting, 1 active not recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow ONC206: new trials by email Literature Review of ONC206 trials Research Report on ONC206
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma JZP3507 - Meningioma | Phase 2 | Recruiting | Jazz Pharmaceuticals | 30 | 2026-07-16 | 2026-10-29 |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma ONC206, ONC206: Dose 1, ONC206: Dose 2 - Advanced Pheochromocytoma and Paraganglioma, PCPG | Phase 2 | Recruiting | Jazz Pharmaceuticals | 90 | 2026-01-02 | 2026-10-29 |
| ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors ONC206, Standard of Care Radiation Therapy, Optional Proton (1H) MR spectroscopy (MRS) - Diffuse Midline Glioma (DMG), Glioblastoma | Phase 1 | Recruiting | Sabine Mueller, MD, PhD | 208 | 2021-08-23 | 2026-06-11 |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms ONC206 - Central Nervous System Neoplasms, Glioblastoma | Phase 1 | Active not recruiting | Jazz Pharmaceuticals | 35 | 2020-10-26 | 2026-11-09 |
Central Nervous System Neoplasms (2) · Ependymoma (2) · Glioblastoma (2) · Meningioma (2) · Astrocytoma (1) · Choroid Plexus Neoplasms (1) · Glioma (1) · Gliosarcoma (1) · Medulloblastoma (1) · Neoplasms, Neuroepithelial (1) · Neuroectodermal Tumors (1) · Neuroectodermal Tumors, Primitive (1) · Oligodendroglioma (1) · Paraganglioma (1) · Pinealoma (1)
Jazz Pharmaceuticals (3) · Sabine Mueller, MD, PhD (1)
United States (4) · Netherlands (1) · Switzerland (1)
PMID 35157764, PMID 35417530, PMID 41256696
R01CA266596 (1)